H E M a T O L O G Y R E V I E W S — V O L U M E 1 , 2 0
Total Page:16
File Type:pdf, Size:1020Kb
hematology reviews — volume 1, 2009 HEMATOLOGY REVIEWS is published by PAGEPress Publications. The journal is completely free online at www.pagepress.org/hr Publishing costs are offset by a publication fee charged to authors. For more information and manuscript submission: www.pagepress.org/hr Copyright Information All works published in PAGEPress journals are subject to the terms of the Creative Commons Attribution License (http:⁄⁄creativecommons.org/licenses/by-nc/3.0) unless otherwise noted. Copyright is retained by the authors. Any non-commercial reuse is permitted if the original author and source are credited. Correspondence Our publishing offices are located in via Giuseppe Belli 4, 27100 Pavia, Italy. Our telephone number is +39.0382.1751762 and our fax number is +39.0382.1750481. E-mail: [email protected] All PAGEPress journals are Open Access. PAGEPress articles are freely available online and deposited in a public archive immediately upon publication. HEMATOLOGY REVIEWS ISSN 1970-6804 - eISSN 1970-6790 Editor-in-Chief Giovanni Martinelli, Bologna, Italy Deputy Editor Francesca Palandri, Italy Editorial Board Giuliana Alimena, Italy David Dingli, USA Muller Fabbri, USA Mario Federico, USA Francesca Gualandi, Italy Jean-Luc Harousseau, France Karl-Anton Kreuzer, Germany Delong Liu, USA Hans E. Johnsen, Denmark Taira Maekawa, Japan Anne F. McGettrick, Ireland Ruben Mesa, USA Markus Raderer, Austria Manuela Schmidinger, Austria Evangelos Terpos, Greece Elisabeth Walsby, UK Editorial Staff Nicole Pezzolo, Managing Editor Cristiana Poggi, Production Editor Anne Freckleton, Copy Editor Jeanette Mitchell, Copy Editor Filippo Lossani, Technical Support HEMATOLOGY REVIEWS 2009; Volume 1 Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib? Giovanni Martinelli, Cristina Papayannidis, Ilaria Iacobucci, Simona Soverini, Daniela Cilloni, Michele Baccarani. 1 Double versus single high-dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area Bo Björkstrand, Tobias W. Klausen,Kari Remes,3 Astrid Gruber, Lene M. Knudsen, Olav J. Bergmann, Stig Lenhoff, Hans E. Johnsen. 9 Tuberculosis associated thrombocytopenic purpura: effectiveness of antituberculous therapy Raphael Borie, Claire Fieschi, Eric Oksenhendler, Lionel Galicier. 14 Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy Zhenshu Xu, Shundong Cang, Ting Yang, Delong Liu. 17 Bacterial contamination of platelet concentrates: pathogen detection and inactivation methods Dana Védy, Daniel Robert, Danielle Gasparini, Giorgia Canellini, . 22 Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity Ashraf H. ElGhandour, Manal El Sorady, Sahar Azab, Mohammed ElRahman . 29 Palliative splenic irradiation in primary and post pv/et myelofibrosis: outcomes and toxicity of three radiation schedules Mario Federico, Guido Pagnucco, Antonio Russo, Giovanni Cardinale, Patrizia Guerrieri, Francesco Sciumè, Catherine Symonds, Letizia Cito, Sergio Siragusa, Nicola Gebbia, Roberto Lagalla, Massimo Midiri, Antonio Giordano, Paolo Montemaggi . 33 MicroRNAs: tiny players with a big role in the pathogenesis of leukemias and lymphomas Francesca Fanini, Ivan Vannini, Muller Fabbri. 40 Histone deacetylase inhibitors in multiple myeloma Sarah Deleu, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, Karin Vanderkerken . 46 The role of JAK2 abnormalities in hematologic neoplasms Mohammed K. Alabdulaali . 56 Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial Hans E. Johnsen, Lene M. Knudsen, Anne K Mylin, Peter Gimsing, Henrik Gregersen, Niels Abildgaard, Nils Frost Andersen, Torben Plesner, Annette Vangsted, Torben Mourits-Andersen, on behalf of the Nordic Myeloma Study Group . 62 Maintenance therapy in multiple myeloma Jean-Luc Harousseau . 65 [Hematology Reviews 2009; volume 1] Transcriptional regulation of the human ALDH1A1 promoter by the oncogenic homeoprotein TLX1/HOX11 Kim L. Rice, Mansour Heidari, Ross H. Taplin, Ursula R. Kees, Wayne K. Greene . 70 Communication between bone marrow niches in normal bone marrow function and during hemopathies progression Sara Lamorte, Leonor Remédio, Sergio Dias . 80 A sensitivity comparison of the Quick and Owren prothrombin time methods in oral anticoagulant therapy Juha Horsti . 87 Clear cell renal cell carcinoma with vaginal and brainmetastases: a case report and literature review Tobe Momah, Etwaru Dhanan, Phillip Xiao, Vasantha Kondamudi . 92 A case of follicular lymphoma complicated with mesenteric panniculitis Yotaro Tamai, Osamu Imataki, Ichiro Ito, Kimihiro Kawakami . 94 Massive pleural effusion due to IgG multiple myeloma Kathryn J. Lang, Surjit Lidder, Robin Aitchison . 97 The progress of prothrombin time measurement Juha Horsti . 99 Confirmation of the validity of using birth MCV for the diagnosis of alpha thalassemia trait Akram M. Al-Hilali, Aisha M. Al-Jallaf, Sajida Chunkasseril. 103 Best practices for transfusion for patients with sickle cell disease Ted Wun, Kathryn Hassell . 106 [Hematology Reviews 2009; volume 1] Spreading information in science PAGEPress aims to be a truly international organization by providing access to the scientific literature to anyone, anywhere, by publishing works from every nation, and by engaging a geographically diverse group of scientists in the editorial process. PAGEPress aims to create a new chapter of the so-called Library of Science using Open Access PAGEPress is a brand of MeditGroup, an Italian media PAGEPress OpenAccess journals are an ideal platform company which has been developing services for the for the publication of your research enabling you to reach international scientific community since 1992. the widest available audience of professionals in your PAGEPress is now launching a range of peer-reviewed, field of expertise. Publication in our journals means that open access scholarly journals covering several scientific your research articles will be available for immediate fields. free access online. PAGEPress shortens the time needed All material published by PAGEPress, whether submit- before publication, offers a high quality peer review sys- ted to or created by PAGEPress, is published under an tem and submission to many online OpenAccess reposi- open access license that lets others remix, and build tories. upon your work non-commercially, and although their Many researchers are choosing to publish in our new works must also acknowledge you and be non-com- OpenAccess journals thanks to the promise of a quick mercial, they don’t have to license their derivative works and discerning peer review, immediate free access to on the same terms. your research, the wide range and prestige of our jour- PAGEPress strives to set the highest standards of nals, and much much more. Find out more about why excellence in all aspects of its activities, whether this be many authors choose to publish with us and consider the its journal image, its style of presentation, the quality of advantages to be gained. the editorial process at every level, the transparency of All research articles published by PAGEPress are sub- its operations and procedures, its accessibility to the sci- ject to a rigorous peer review system. The Editorial entific community and the public, and its educational Board of each journal is responsible for the form the value. peer review process will take. Find out more about the PAGEPress is committed to a fair and rigorous editori- peer review policy for each of our journals secure in the al process. The decision to accept an article for publica- knowledge that every article you submit to tion will be based purely on scientific quality and impor- a PAGEPress journal will enjoy a speedy and efficient tance. appraisal. PAGEPress welcomes and actively seeks opportunities PAGEPress allows and encourages authors to deposit to work together with any group (scientific/scholarly both their pre- and post-prints in open-access institu- societies, physicians, patient advocacy groups, educa- tional archives or repositories. The primary benefit of tional organizations) and any publisher who shares our self-archiving is reaching a larger audience which commitment to Open Access and to making scientific enhances the visibility and impact of your research. information available for the benefit of science and the public good. [Hematology Reviews 2009; volume 1] Submit your paper to www.pagepress.org/hr Hematology Reviews 2009; volume 1:e1 Aurora kinase inhibitors: blastic phase (BP). Imatinib (Gleevec, Glivec; STI571), a relatively selective tyrosine kinase Correspondence: Giovanni Martinelli, which role in the treatment of inhibitor that blocks the catalytic activity of Institute of Hematology and Medical Oncology chronic myelogenous leukemia Bcr-Abl, is now the first-line treatment for all "Seràgnoli", University of Bologna, newly diagnosed CML patients. Despite excel- via Massarenti, 9 - 40138 Bologna, Italy patients resistant to imatinib? E-mail: [email protected] lent clinical results, there is still a need to Giovanni Martinelli,1 improve therapy for patients with CML and Key words: chronic myeloid leukemia, Bcr-Abl, + Cristina Papayannidis,1 Ilaria Iacobucci,1 Ph ALL. More than 80% of newly diagnosed imatinib, resistance,